Health Care • Biotechnology: Pharmaceutical Preparations
$0.76 ▼ -0.15
(-16.31%)
MKT CAP: $4.6M • VOL: 1.13M
52W L $1 52W H $5
ROARABLE / RQD
D- • 41/100
PIOTROSKI
1 / 9
AZTR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $7.5K | $686.0K |
| YoY Revenue Growth % | — | -98.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.0M | -$11.0M | -$7.5M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$11.0M | -$9.0M | -$11.3M |
| EBITDA (Normalized) | -$10.9M | -$11.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$11.2M | -$10.2M | -$7.4M |
| Capital Expenditures (CapEx) | $24.2K | $8.6K | — |
| Free Cash Flow (FCF) | -$11.2M | -$10.2M | -$7.4M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $2.1M | $4.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.8M | $5.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AZTR.